Portal Biotechnologies
Builds universal infrastructure for cell engineering across drug discovery and cell therapy
$9MUndisclosed
Role not disclosedActivity from announced rounds
NFX is the investment firm identified through founding partner Gigi Levi-Weiss in Remepy’s announcement and through Omri Amirav Drory’s TwoStep relationship.
Remepy combines medicines with therapeutic applications. TwoStep develops targeted cancer therapies, while Starcloud develops orbital computing. The event records identify the firm without inferring a particular fund.
Builds universal infrastructure for cell engineering across drug discovery and cell therapy